According to this article in Clinical Trials Today, the contract research organization Parexel has completed a Chinese bridging study to be conducted outside of China at their Los Angeles facility. Parexel recently acquired California Clinical Trials (CCT), which does a number of ethnobridging studies.
Michelle Middle, corporate vice president and worldwide head of Clinical Pharmacology at Parexel mentions:
“The goal of Parexel clinical pharmacology is to help sponsors to get as much information as soon as possible in drug development.”
Briding studies have grown increasingly important to clinical research, as more and more companies are looking to cut back on costs.
Search This Blog
Blog Archive
-
▼
2008
(97)
-
▼
November
(15)
- Clinical Trials Market Expected to Grow in India D...
- Parexel Completes Chinese Bridging Study
- CROs Under Fire
- CRO BioReliance Enters Tech-Development
- India's clinical trials not affected by the recession
- MarketWatch: Quintiles, SAS Announce Development o...
- Biotrial, Full-Service CRO and European Leader in ...
- Economic Crisis Presents an Opportunity for the In...
- Mayo Clinic Pulls Out of Clinical Services
- MarketWatch: EyeGate Pharma Enrolls First Dry Eye ...
- Outsourced Clinical Trials Going Through a Rough P...
- Kendle sees revenue increase
- Nurse dismissed for error in clinical trials
- Nigeria Opens Clinical Trial Center
- India, China, Latin America and CEE as Clinical Tr...
-
▼
November
(15)
No comments:
Post a Comment